New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease...
New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of...
VANCOUVER, British Columbia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned...
VANCOUVER, British Columbia, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned...
VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned...
VANCOUVER, British Columbia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s...
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned...
Planning Phase II Trial VANCOUVER, B.C., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a...
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash...
University of Florida to Complete Prototype Development VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and...
Planning Phase II Trial VANCOUVER, B.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a...
VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH...
VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.